CYT 500 Lu 177

Drug Profile

CYT 500 Lu 177

Alternative Names: 177Lu-CYT-500

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Cytogen Corporation
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Prostate-cancer in USA (Parenteral)
  • 28 Feb 2007 Phase-I clinical trials in Prostate cancer in USA (Parenteral)
  • 06 Apr 2006 Cytogen Corporation has filed an IND for CYT 500 with the US FDA for Metastatic hormone-refractory prostate cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top